PresseBox
Pressemitteilung BoxID: 436397 (Carl Zeiss MicroImaging GmbH)
  • Carl Zeiss MicroImaging GmbH
  • Carl-Zeiss-Promenade 10
  • 07740 Jena
  • http://www.zeiss.de
  • Ansprechpartner
  • Jochen Tham
  • +49 (3641) 64-3949

Carl Zeiss Obtains Licence from University of California for Illumination Technique

Carl Zeiss and the University of California, San Francisco, agree on marketing rights for light sheet fluorescence microscopy illumination techniques

(PresseBox) (Jena/San Francisco, California USA, ) Carl Zeiss has received a licence from the University of California in San Francisco (UCSF) for the commercialization of "Multidirectional Selective Plane Illumination Microscopy" (mSPIM), an advanced illumination technique for light sheet fluorescence microscopy.

Light sheet fluorescence microscopy is a relatively new application of the concept of light sheet illumination in biology and the life sciences. It is ideally suited for live imaging of up to millimeter sized fluorescently labeled specimens for days under certain physiological conditions and with minimum photo-induced damage.

The mSPIM technique was developed by Dr. Jan Huisken at the UCSF. It reduces absorption and scattering artifacts and provides an evenly illuminated focal plane. By alternating illumination of the sample from multiple sides, mSPIM overcomes two common problems in light sheet imaging techniques: shadowing effects in the excitation path and spreading of the light sheet by scattering in the sample.

The agreement grants Carl Zeiss the right to integrate the mSPIM technology in its microscopy systems. The first commercial light sheet fluorescence microscope (LSFM, also known as "selective plane illumination microscope" or "SPIM") for multidimensional, ultrafast and long- term timelapse imaging of live specimens is currently being developed at Carl Zeiss in Germany.

Together with Carl Zeiss' innovative concepts for light sheet microscopy, the licensing of mSPIM represents another big step forward in 3D microscopy of living specimens. This benefits diverse fields such as developmental biology, cell biology, neurobiology, stem cell research and marine biology.

UCSF Disclaimer for Industry Releases:

The information stated above was prepared by Carl Zeiss and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Carl Zeiss, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Carl Zeiss MicroImaging GmbH

The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and opto-electronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. During fiscal year 2009/10 the group of companies generated revenues of around EUR 2.98 billion. From fiscal year 2010/11 onward, eyeglass lens manufacturer Carl Zeiss Vision will be integrated as an autonomous business group (revenues of EUR 880 million in fiscal year 2009/10). The Carl Zeiss Group now has approximately 24,000 employees, including more than 10,000 in Germany. The Carl Zeiss business groups hold leading positions in their markets. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).

Carl Zeiss MicroImaging

Carl Zeiss MicroImaging GmbH comprises the Microscopy Group of Carl Zeiss. Carl Zeiss MicroImaging is one of the leading manufacturers of microscope systems and offers total solutions for biomedical research, the healthcare sector and high-tech industries. Its product line spans a broad spectrum from light microscopes and systems for laser scanning microscopy and spectrometry to hardware and software for image processing and documentation. Carl Zeiss MicroImaging GmbH is headquartered in Jena, Germany. Other manufacturing and development sites are located in Goettingen and Munich. In fiscal year 2009/10 the Microscopy Group at Carl Zeiss generated revenues of approximately EUR 397 million with a global workforce of around 1,700 people.